Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Dendermonde – page 9

2 119 clinical trials in Dendermonde, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Dendermonde at a glance
2 119
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 119 trials in Dendermonde

Open in trial search

Study of NTLA-2001 for Patients with Transthyretin Amyloidosis and Heart Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Intellia Therapeutics Inc.

Neutropenia

Recruiting

Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor
  • Sponsor:X4 Pharmaceuticals Inc.

Prostate cancer

Recruiting

Study on Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan for Adults with Prostate Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:Novartis Pharma AG

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer

Recruiting

Study of Tersolisib and a drug combination for adults with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Efficacy and Safety of Three Different Doses of Pirtobrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Previously Received BTK Inhibitor Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

First-line treatment of metastatic non‑small cell lung cancer with high PD‑L1 expression: ivonescimab versus pembrolizumab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivonescimab
  • Sponsor:Summit Therapeutics Inc.

Phase 2 Study of Oral VS-7375 in Adults with Advanced KRAS G12D‑Mutated Non‑Small Cell Lung Cancer Previously Treated

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:GFH375
  • Sponsor:Verastem Inc.

Efficacy and Safety of RO7568282 in Adults with Early Symptomatic Alzheimer’s Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Study of BI 764532 with drug combination in patients with extensive‑stage small cell lung cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Efficacy and Safety of BI 1015550 in Adults with Fibrosing Interstitial Lung Disease at Risk of Disease Progression: A Randomized, Placebo‑Controlled Trial

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

A Phase 2 Study of VS-7375 Alone or with Drug Combination in Patients with Metastatic KRAS G12D‑Mutated Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Verastem Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Dendermonde

What the registry says about research in the country

01 Cardiovascular Disease Prevention

Innovative research focusing on lipoprotein reduction and prevention of major cardiovascular events in patients with established CVD. Studies evaluating new therapeutic approaches for reducing cardiovascular risks.

  • Atherosclerotic cardiovascular disease prevention
  • Lipid management therapies
  • Cardiovascular risk reduction

Cutting-edge trials examining novel compounds for improving cardiovascular outcomes.

02 Cardiac Rhythm Disorders

Studies investigating treatments for atrial fibrillation and stroke prevention. Research comparing new anticoagulation therapies with established treatments for preventing systemic embolism.

  • Stroke prevention in AF
  • Novel anticoagulants
  • Cardioembolic event prevention

Advanced clinical research focusing on improving outcomes in cardiac rhythm management.

03 Specialized Cardiac Conditions

Research targeting rare cardiac conditions including transthyretin amyloidosis with cardiomyopathy. Evaluation of innovative treatments for specific cardiac pathologies.

  • Cardiomyopathy management
  • Rare cardiac diseases
  • Targeted therapeutic approaches

Focused studies on improving survival rates and quality of life in specialized cardiac conditions.

04 Stroke Management

Clinical trials examining treatments for acute ischemic stroke and high-risk transient ischemic attacks. Studies evaluating new therapeutic options for stroke prevention and management.

  • Post-stroke care
  • TIA management
  • Stroke prevention strategies

Development of advanced treatments for better stroke outcomes.

05 Oncology Research

Studies investigating the role of acetylsalicylic acid in improving survival rates for colon cancer patients. Research focused on preventing cancer recurrence after surgical intervention.

  • Colon cancer treatment
  • Post-surgical care
  • Cancer recurrence prevention

Innovative approaches in cancer survival improvement strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.